Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pioneer's FortrOss bone filler receives FDA clearance

This article was originally published in Clinica

Executive Summary

Pioneer Surgical Technology's FortrOss bone graft substitute has received US FDA 510(k) clearance. The scaffold, which is used for the in-growth of bone and other connective tissues, combines the firm's NanOss nanotechnology material (originally developed by Angstrom Medica) and the osteoprotective E-Matrix scaffold, from Encelle. Marquette, Michigan-based Pioneer acquired Encelle in June 2007 and Angstrom in October 2007 (see Clinica Nos 1259, p 18 & 1280, p 15). Pioneer claims that FortrOss is the most advanced bone filler on the market, as it is designed to mimic human bone tissue. This means that bone cells recognise it as native tissue and have a high affinity for it.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT041738

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel